Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bines, J.
Right arrow Articles by Cobleigh, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bines, J.
Right arrow Articles by Cobleigh, M. A.

Journal of Clinical Oncology, Vol 14, 1718-1729, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer

J Bines, DM Oleske and MA Cobleigh
Department of Internal Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612, USA.

PURPOSE: Adjuvant chemotherapy for breast cancer causes significant changes in ovarian function. More young women survive breast cancer than ever before and they are at risk of the sequelae of early menopause. We attempted to (1) define menopausal status in the setting of adjuvant chemotherapy; (2) define chemotherapy-related amenorrhea (CRA); (3) document rates of permanent amenorrhea, temporary amenorrhea, and oligomenorrhea among different regimens; and (4) analyze variables that influence ovarian function. DESIGN: We reviewed reports of the effects of adjuvant chemotherapy for breast cancer on ovarian function in premenopausal women. We searched Medline and Cancerlit from 1966 to 1995 on the following terms: breast neoplasms; chemotherapy, adjuvant; menstruation disorders; premature menopause, and amenorrhea. Further references were obtained from reports retrieved in the initial search. RESULTS: A uniform definition of menopause and CRA is lacking. The wide range of CRA rates reported in adjuvant chemotherapy trials is a result, at least in part, of this problem. The average CRA rate reported in regimens based on cyclophosphamide, methotrexate, and fluorouracil (CMF) is 68% (95% confidence interval [CI], 66% to 70%), with a range of 20% to 100%. CRA incidence varies with age, cytotoxic agent, and cumulative dose. CONCLUSION: Ovarian damage is the most significant long-term sequela of adjuvant chemotherapy in premenopausal breast cancer survivors. We suggest a common definition of the following important terms: menopausal status, CRA (early and late), temporary CRA, and oligomenorrhea in the setting of adjuvant treatment. With uniform definitions in place, regimens can be more precisely compared with respect to this important complication.


This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
R. Beck-Fruchter, A. Weiss, and E. Shalev
GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data
Hum. Reprod. Update, November 1, 2008; 14(6): 553 - 561.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
K. Absolom, C. Eiser, L. Turner, W. Ledger, R. Ross, H. Davies, R. Coleman, B. Hancock, J. Snowden, D. Greenfield, et al.
Ovarian failure following cancer treatment: current management and quality of life
Hum. Reprod., November 1, 2008; 23(11): 2506 - 2512.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. L. Hershman, D. J. McMahon, K. D. Crew, S. Cremers, D. Irani, G. Cucchiara, L. Brafman, and E. Shane
Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer
J. Clin. Oncol., October 10, 2008; 26(29): 4739 - 4745.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Azim, M. Costantini-Ferrando, and K. Oktay
Safety of Fertility Preservation by Ovarian Stimulation With Letrozole and Gonadotropins in Patients With Breast Cancer: A Prospective Controlled Study
J. Clin. Oncol., June 1, 2008; 26(16): 2630 - 2635.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Lie Fong, P.J. Lugtenburg, I. Schipper, A.P.N. Themmen, F.H. de Jong, P. Sonneveld, and J.S.E. Laven
Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies
Hum. Reprod., March 1, 2008; 23(3): 674 - 678.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Parton and I. E. Smith
Controversies in the Management of Patients With Breast Cancer: Adjuvant Endocrine Therapy in Premenopausal Women
J. Clin. Oncol., February 10, 2008; 26(5): 745 - 752.
[Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
H. C. F. Moore
Ovarian Failure after Chemotherapy for Breast Cancer and the Role of Gonadotropin-releasing Hormone Analogs in Protection of Ovarian Function
ASCO Educational Book, January 1, 2008; 2008(1): 39 - 42.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. L. De Bruin, J. Huisbrink, M. Hauptmann, M. A. Kuenen, G. M. Ouwens, M. B. van't Veer, B. M. P. Aleman, and F. E. van Leeuwen
Treatment-related risk factors for premature menopause following Hodgkin lymphoma
Blood, January 1, 2008; 111(1): 101 - 108.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
C. Duffy, K. Perez, and A. Partridge
Implications of Phytoestrogen Intake for Breast Cancer
CA Cancer J Clin, September 1, 2007; 57(5): 260 - 277.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
The Adjuvant Breast Cancer Trials Collaborative Gr
Ovarian Ablation or Suppression in Premenopausal Early Breast Cancer: Results From the International Adjuvant Breast Cancer Ovarian Ablation or Suppression Randomized Trial
J Natl Cancer Inst, April 4, 2007; 99(7): 516 - 525.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. L. Greenspan, R. K. Bhattacharya, S. M. Sereika, A. Brufsky, and V. G. Vogel
Prevention of Bone Loss in Survivors of Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 131 - 136.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Walshe, N. Denduluri, and S. M. Swain
Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer
J. Clin. Oncol., December 20, 2006; 24(36): 5769 - 5779.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Hirbe, E. A. Morgan, O. Uluckan, and K. Weilbaecher
Skeletal complications of breast cancer therapies.
Clin. Cancer Res., October 15, 2006; 12(20): 6309s - 6314s.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Oktay, A. Hourvitz, G. Sahin, O. Oktem, B. Safro, A. Cil, and H. Bang
Letrozole Reduces Estrogen and Gonadotropin Exposure in Women with Breast Cancer Undergoing Ovarian Stimulation before Chemotherapy
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3885 - 3890.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
R.A. Anderson, A.P.N. Themmen, A.A. -Qahtani, N.P. Groome, and D.A. Cameron
The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer
Hum. Reprod., October 1, 2006; 21(10): 2583 - 2592.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
J. Donnez, B. Martinez-Madrid, P. Jadoul, A. Van Langendonckt, D. Demylle, and M.-M. Dolmans
Ovarian tissue cryopreservation and transplantation: a review
Hum. Reprod. Update, September 1, 2006; 12(5): 519 - 535.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Roche, P. Kerbrat, J. Bonneterre, P. Fargeot, P. Fumoleau, A. Monnier, P. Clavere, M.-J. Goudier, P. Chollet, J.-P. Guastalla, et al.
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial
Ann. Onc., August 1, 2006; 17(8): 1221 - 1227.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. E. Smith, M. Dowsett, Y.-S. Yap, G. Walsh, P. E. Lonning, R. J. Santen, and D. Hayes
Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines
J. Clin. Oncol., June 1, 2006; 24(16): 2444 - 2447.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Sonmezer and K. Oktay
Fertility preservation in young women undergoing breast cancer therapy.
Oncologist, May 1, 2006; 11(5): 422 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
L. B. Michaud and S. Goodin
Cancer-treatment-induced bone loss, part 1
Am. J. Health Syst. Pharm., March 1, 2006; 63(5): 419 - 430.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Petrek, M. J. Naughton, L. D. Case, E. D. Paskett, E. Z. Naftalis, S. E. Singletary, and P. Sukumvanich
Incidence, Time Course, and Determinants of Menstrual Bleeding After Breast Cancer Treatment: A Prospective Study
J. Clin. Oncol., March 1, 2006; 24(7): 1045 - 1051.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Vehmanen, I. Elomaa, C. Blomqvist, and T. Saarto
Tamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual Status
J. Clin. Oncol., February 1, 2006; 24(4): 675 - 680.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Del Mastro, T. Catzeddu, L. Boni, C. Bell, M. R. Sertoli, C. Bighin, M. Clavarezza, D. Testa, and M. Venturini
Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients
Ann. Onc., January 1, 2006; 17(1): 74 - 78.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
K.L.T. Schmidt, C. Y. Andersen, A. Loft, A.G. Byskov, E. Ernst, and A. N. Andersen
Follow-up of ovarian function post-chemotherapy following ovarian cryopreservation and transplantation
Hum. Reprod., December 1, 2005; 20(12): 3539 - 3546.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Behringer, K. Breuer, T. Reineke, M. May, L. Nogova, B. Klimm, T. Schmitz, L. Wildt, V. Diehl, and A. Engert
Secondary Amenorrhea After Hodgkin's Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin's Lymphoma Study Group
J. Clin. Oncol., October 20, 2005; 23(30): 7555 - 7564.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Thewes, B. Meiser, A. Taylor, K.A. Phillips, S. Pendlebury, A. Capp, D. Dalley, D. Goldstein, R. Baber, and M.L. Friedlander
Fertility- and Menopause-Related Information Needs of Younger Women With a Diagnosis of Early Breast Cancer
J. Clin. Oncol., August 1, 2005; 23(22): 5155 - 5165.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Vanhuyse, C. Fournier, and J. Bonneterre
Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients
Ann. Onc., August 1, 2005; 16(8): 1283 - 1288.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
B. Simon, S. J. Lee, A. H. Partridge, and C. D. Runowicz
Preserving Fertility After Cancer
CA Cancer J Clin, July 1, 2005; 55(4): 211 - 228.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Oktay, E. Buyuk, N. Libertella, M. Akar, and Z. Rosenwaks
Fertility Preservation in Breast Cancer Patients: A Prospective Controlled Comparison of Ovarian Stimulation With Tamoxifen and Letrozole for Embryo Cryopreservation
J. Clin. Oncol., July 1, 2005; 23(19): 4347 - 4353.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
J. S McCune, D. M Games, and J. L Espirito
Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors
Journal of Oncology Pharmacy Practice, June 1, 2005; 11(2): 37 - 43.
[Abstract] [PDF]

Home page
 J Holist NursHome page
S. Bauer-Wu and C. J. Farran
Meaning in Life and Psycho-Spiritual Functioning: A Comparison of Breast Cancer Survivors and Healthy Women
J Holist Nurs, June 1, 2005; 23(2): 172 - 190.
[Abstract] [PDF]

Home page
 JCOHome page
S. Dellapasqua, M. Colleoni, R. D. Gelber, and A. Goldhirsch
Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1736 - 1750.
[Full Text] [PDF]

Home page
 Ann OncolHome page
R. Arriagada, M. G. Le, M. Spielmann, L. Mauriac, J. Bonneterre, M. Namer, T. Delozier, C. Hill, and T. Tursz
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy
Ann. Onc., March 1, 2005; 16(3): 389 - 396.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
Z. Blumenfeld and A. Eckman
Preservation of Fertility and Ovarian Function and Minimization of Chemotherapy-Induced Gonadotoxicity in Young Women by GnRH-a
J Natl Cancer Inst Monographs, March 1, 2005; 2005(34): 40 - 43.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
K. Lutchman Singh, M. Davies, and R. Chatterjee
Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing
Hum. Reprod. Update, January 1, 2005; 11(1): 69 - 89.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. M. Prowell and N. E. Davidson
What Is the Role of Ovarian Ablation in the Management of Primary and Metastatic Breast Cancer Today?
Oncologist, September 1, 2004; 9(5): 507 - 517.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
M. Sonmezer and K. Oktay
Fertility preservation in female patients
Hum. Reprod. Update, May 1, 2004; 10(3): 251 - 266.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. de Haes, M. Olschewski, M. Kaufmann, M. Schumacher, W. Jonat, and W. Sauerbrei
Quality of Life in Goserelin-Treated Versus Cyclophosphamide + Methotrexate + Fluorouracil-Treated Premenopausal and Perimenopausal Patients With Node-Positive, Early Breast Cancer: The Zoladex Early Breast Cancer Research Association Trialists Group
J. Clin. Oncol., December 15, 2003; 21(24): 4510 - 4516.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Ganz, G. A. Greendale, L. Petersen, B. Kahn, and J. E. Bower
Breast Cancer in Younger Women: Reproductive and Late Health Effects of Treatment
J. Clin. Oncol., November 15, 2003; 21(22): 4184 - 4193.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. E. Hillner, J. N. Ingle, R. T. Chlebowski, J. Gralow, G. C. Yee, N. A. Janjan, J. A. Cauley, B. A. Blumenstein, K. S. Albain, A. Lipton, et al.
American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer
J. Clin. Oncol., November 1, 2003; 21(21): 4042 - 4057.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. P. Winer, C. Hudis, H. J. Burstein, J. Bryant, R. T. Chlebowski, J. N. Ingle, S. B. Edge, E. P. Mamounas, R. Gelber, J. Gralow, et al.
American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting
J. Clin. Oncol., July 1, 2003; 21(13): 2597 - 2599.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
K. Oktay, E. Buyuk, O. Davis, I. Yermakova, L. Veeck, and Z. Rosenwaks
Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen
Hum. Reprod., January 1, 2003; 18(1): 90 - 95.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. A. Emens and N. E. Davidson
Adjuvant Hormonal Therapy for Premenopausal Women with Breast Cancer
Clin. Cancer Res., January 1, 2003; 9(1): 486S - 494S.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. Mintzer, J. Glassburn, B. A. Mason, and D. Sataloff
Breast Cancer in the Very Young Patient: A Multidisciplinary Case Presentation
Oncologist, December 1, 2002; 7(6): 547 - 554.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. Van Praagh, H. Cure, B. Leduc, S. Charrier, G. Le Bouedec, J.-L. Achard, J.-P. Ferriere, V. Feillel, M. de Latour, J. Dauplat, et al.
Efficacy of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Methotrexate (VEM) as Neoadjuvant Treatment in 89 Patients with Operable Breast Cancer
Oncologist, October 1, 2002; 7(5): 418 - 423.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Arriagada, M. Spielmann, S. Koscielny, T. Le Chevalier, T. Delozier, M. Ducourtieux, T. Tursz, and C. Hill
Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen
Ann. Onc., September 1, 2002; 13(9): 1378 - 1386.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
National Institutes of Health Consensus Developmen
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 5 - 15.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
N. E. Davidson
Ovarian Ablation as Adjuvant Therapy for Breast Cancer
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 67 - 71.
[Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
G. N Hortobagyi
Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 72 - 79.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
P. A. Ganz
Impact of Tamoxifen Adjuvant Therapy on Symptoms, Functioning, and Quality of Life
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 130 - 134.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Ganz and G. A. Greendale
Menopause and Breast Cancer: Addressing the Secondary Health Effects of Adjuvant Chemotherapy
J. Clin. Oncol., July 15, 2001; 19(14): 3303 - 3305.
[Full Text] [PDF]

Home page
 JCOHome page
C. L. Shapiro, J. Manola, and M. Leboff
Ovarian Failure After Adjuvant Chemotherapy Is Associated With Rapid Bone Loss in Women With Early-Stage Breast Cancer
J. Clin. Oncol., July 15, 2001; 19(14): 3306 - 3311.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000
J Natl Cancer Inst, July 4, 2001; 93(13): 979 - 989.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. L. Shapiro and A. Recht
Side Effects of Adjuvant Treatment of Breast Cancer
N. Engl. J. Med., June 28, 2001; 344(26): 1997 - 2008.
[Full Text] [PDF]

Home page
 Reproductive SciencesHome page
Z. Blumenfeld
Ovarian Rescue/Protection from Chemotherapeutic Agents
Reproductive Sciences, January 1, 2001; 8(1_suppl): S60 - S64.
[Abstract] [PDF]

Home page
 NEJMHome page
H. J. Burstein and E. P. Winer
Primary Care for Survivors of Breast Cancer
N. Engl. J. Med., October 12, 2000; 343(15): 1086 - 1094.
[Full Text] [PDF]

Home page
 Reproductive SciencesHome page
Z. Blumenfeld, I. Avivi, M. Ritter, and J. M. Rowe
Preservation of Fertility and Ovarian Function and Minimizing Chemotherapy-Induced Gonadotoxicity in Young Women
Reproductive Sciences, September 1, 1999; 6(5): 229 - 239.
[Abstract] [PDF]

Home page
 JCOHome page
P. J. Goodwin, M. Ennis, K. I. Pritchard, M. Trudeau, and N. Hood
Risk of Menopause During the First Year After Breast Cancer Diagnosis
J. Clin. Oncol., August 1, 1999; 17(8): 2365 - 2365.
[Abstract] [Full Text] [PDF]